Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs
Radiolabeled receptor-binding peptides have become an important class of radiopharmaceuticals in nuclear oncology. The most prominent examples of successful peptide-based radiotherapy are radiolabeled somatostatin analogs for imaging and treatment of patients with progressive neuroendocrine tumors. Immunohistological studies demonstrating somatostatin receptor expression in differentiated and medullary thyroid cancer have provided the rationale for the use of radiolabeled somatostatin analogs in diagnosis and treatment of thyroid cancers. Accordingly, 90Yttrium-, 177Lutetium-, and 111Indium-labeled somatostatin analogs have been evaluated for treatment of patients with iodine-refractory differentiated and medullary thyroid cancer. In differentiated thyroid cancer, the reported rates of disease control, defined as responses plus stable disease, vary between 20 and 56 %. Studies on the follow-up after treatment revealed a time to progression between 9 and 43 months. In medullary thyroid cancer, the reported rates of disease control vary between 42 and 67 %. In both entities, responders have prolonged survival compared with nonresponders.
KeywordsThyroid Cancer Medullary Thyroid Carcinoma Medullary Thyroid Differentiate Thyroid Cancer Medullary Thyroid Cancer
- Ball DW, Baylin SB et al. (2000). Medullary thyroid carcinoma. In: Braverman LE, Utiger RE (eds.) Lippincott Williams & Wilkins, Philadelphia, pp 930–943Google Scholar
- Behr TM, Gratz S et al (1997) Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 80(12 Suppl):2436–2457PubMedCrossRefGoogle Scholar
- Schlumberger M, Gardet P et al (1991) External radiotherapy and chemotherapy in MTC patients. In: Calmettes C, Guliana JM (eds.) Colloque INSERM/John Libbey, Eurotext Ltd, Paris, France pp. 211, 213–220Google Scholar
- Villard L, Romer A et al (2012) Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30(10):1100–1106Google Scholar